Your browser doesn't support javascript.
loading
[Concomitant treatment with gemcitabine and radiotherapy in patients with advanced stages of epidermoid carcinoma originating in the head and neck. A phase II sutdy]. / Tratamiento concomitante con gemcitabina y radioterapia en pacientes con carcinoma epidermoide locorregionalmente avanzado de cabeza y cuello. Estudio fase II.
Bustamante-Valles, Flor de Thé; Calva-Espinosa, Angel Luis; Gallegos-Hernández, José Francisco; Villalobos-Valencia, Ricardo; Castruita, Ana Lilia; Silva, Juan Alejandro; Flores-Díaz, Rutilio.
Afiliação
  • Bustamante-Valles Fde T; Departamentos de Oncología Médica, Hospital de Oncología, Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico D. F., Mexico.
Gac Med Mex ; 142(2): 91-4, 2006.
Article em Es | MEDLINE | ID: mdl-16711540
BACKGROUND: Surgery, radiotherapy or radiotherapy alone (RTA) constitute conventional treatment regimes for advanced stages of squamous cell carcinoma originating in the head and neck mucosa. Nevertheless, the results in advanced regional carcinoma (ARC) are disappointing. The chemotherapy-radiotherapy (CHT-RT) association has shown to be superior to RTA in irresectable disease and in resectable disease it could substitute initial surgery as a rescue alternative. OBJECTIVE: Our objective is to report the response rate and toxicity of concurrent treatment with Gemcitabine and Radiotherapy (GRT) in patients with ARC. In a prospective design, patients with ARC received concurrent GRT; the global, complete and partial response rate as well as toxicity were assessed. MATERIAL AND METHODS: 15 patients were included, 5 women and 10 men, 73% in stage IVa; 13/15 showed a global response (87%), a complete response was observed in 9 cases (60%) (RC) and 2 showed progress. RESULTS: All patients included showed toxicity, the most frequent one was level 4 mucositis in 46%, of this 40% required nutritional support by catheter or gastrostomy. One patient in RC died due to sepsis. None of them suspended treatment. CONCLUSION: The GRT association offers a complete response rate of 60%; nevertheless morbidity was not insignificant; randomized studies with a larger number of patients will be required to allow us to outline the optimal therapeutic scheme.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Desoxicitidina / Neoplasias de Cabeça e Pescoço / Antimetabólitos Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: Es Revista: Gac Med Mex Ano de publicação: 2006 Tipo de documento: Article País de afiliação: México País de publicação: México
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Desoxicitidina / Neoplasias de Cabeça e Pescoço / Antimetabólitos Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: Es Revista: Gac Med Mex Ano de publicação: 2006 Tipo de documento: Article País de afiliação: México País de publicação: México